Upstate Active Clinical Trials

Study Title:

A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-
Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily
Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration
Arm of Pramipexole ER

What is the purpose of the study?

The purpose of this research study is to:
• test the safety and effectiveness of the study drug, P2B001, in treating patients with early Parkinson’s disease

Upstate Institutional Review Board (IRB) Number:

1178214

Study/Protocol ID:

P2B001/003

Study Phase:

Phase III

Patient Age Group:

Adults

Principal Investigator:

Dragos L Mihaila

Who can I contact for more information?

Name: Jacob D Pusey
Phone: 315-464-9767
Email: puseyj@upstate.edu

Return to Previous Page || Search Again